Savara Inc. (NASDAQ:SVRA) Receives $10.14 Average Price Target from Analysts

Savara Inc. (NASDAQ:SVRA) has received an average recommendation of “Moderate Buy” from the eight brokerages that are covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $10.1429.

Several research analysts have issued reports on SVRA shares. William Blair set a $10.00 target price on shares of Savara in a report on Monday, March 16th. HC Wainwright reiterated a “buy” rating on shares of Savara in a report on Monday, March 16th. Wall Street Zen upgraded shares of Savara from a “sell” rating to a “hold” rating in a report on Saturday. Weiss Ratings restated a “sell (d-)” rating on shares of Savara in a report on Tuesday, April 21st. Finally, Oppenheimer started coverage on shares of Savara in a report on Friday, April 24th. They issued an “outperform” rating and a $11.00 price target on the stock.

Institutional Trading of Savara

A number of institutional investors have recently modified their holdings of the company. Osaic Holdings Inc. boosted its holdings in shares of Savara by 6.9% in the 4th quarter. Osaic Holdings Inc. now owns 32,678 shares of the company’s stock valued at $197,000 after buying an additional 2,098 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its holdings in shares of Savara by 3.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 69,536 shares of the company’s stock valued at $420,000 after buying an additional 2,116 shares in the last quarter. Graham Capital Management L.P. boosted its holdings in shares of Savara by 4.9% in the 4th quarter. Graham Capital Management L.P. now owns 56,013 shares of the company’s stock valued at $338,000 after buying an additional 2,615 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Savara by 9.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 33,155 shares of the company’s stock valued at $200,000 after buying an additional 2,859 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Savara by 48.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 9,887 shares of the company’s stock valued at $60,000 after buying an additional 3,205 shares in the last quarter. 87.93% of the stock is currently owned by institutional investors.

Savara Price Performance

Shares of Savara stock opened at $5.26 on Wednesday. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.47 and a quick ratio of 13.47. Savara has a 1 year low of $1.98 and a 1 year high of $7.01. The firm’s 50-day moving average is $5.29 and its two-hundred day moving average is $5.60. The stock has a market cap of $1.08 billion, a price-to-earnings ratio of -9.39 and a beta of 0.26.

Savara (NASDAQ:SVRA) last issued its earnings results on Tuesday, May 12th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.01). As a group, research analysts expect that Savara will post -0.57 earnings per share for the current fiscal year.

About Savara

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.